Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.2021014196 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
JAK-ing up chronic actinic dermatitis with upadacitinib.
Clin Exp Dermatol
January 2024
2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, 'ATTIKON' General University Hospital, Athens, Greece.
JAK-ing up the Response to KIT Inhibition.
J Invest Dermatol
January 2018
Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA. Electronic address:
Only a subset of patients with KIT-mutant melanoma derives clinical benefit from KIT inhibition, and the development of resistance is common. Efforts to improve the efficacy of KIT inhibition are limited by a lack of understanding of the mechanisms underlying response and resistance to treatment. Findings from Delyon et al.
View Article and Find Full Text PDF'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
Curr Opin Hematol
March 2017
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Purpose Of Review: The article discusses the promising agents that are approved or currently under investigation for the treatment of myelofibrosis and reviews the ongoing Janus kinase (JAK) inhibitors-based combinatorial strategies in this setting.
Recent Findings: Myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm with constitutive JAK/STAT activation. The JAK-inhibitor ruxolitinib is the only approved drug for this disease in the United States and Europe based on two randomized phase III studies that demonstrated clinically meaningful reduction in spleen size, improvement in symptoms, quality of life, and an overall survival advantage with prolonged follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!